EUVIMEDEUVIMED entdecken
Crossref

Medical Therapy and Clinical Outcomes in Cardiac Sarcoidosis Patients With Systolic Heart Failure

Daniel Sykora, Melanie Bratcher, Robert Churchill, B Michelle Kim, Mohamed Elwazir, Kathleen Young, Sami Ryan, Nikhil Kolluri, Omar Abou Ezzeddine, John Bois, John Giudicessi, Leslie Cooper und 1 weitere

Circulation Journal · 2024

DOI: 10.1253/circj.cj-24-0205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Journal, 2024. Verfasst von Daniel Sykora und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic School of Graduate Medical Education. Hauptthemen laut MEDLINE: Sarcoidosis, Heart Failure, Systolic, Cardiomyopathies, Stroke Volume. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Center for Clinical and Translational Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiac sarcoidosis (CS) may result in systolic heart failure (heart failure with reduced ejection fraction [HFrEF]), but its response to guideline-directed medical therapy (GDMT) remains uncertain. METHODS AND RESULTS: We investigated 881 patients evaluated for CS to identify those with diagnosed CS, left ventricular ejection fraction (LVEF) ≤40% at diagnosis, and follow-up echocardiogram within 11-24 months. Demographics, LVEF, GDMT as quantified by Kansas City Medical Optimization (KCMO) score, and immunosuppressive treatment were recorded. The primary outcome was a composite of event-free survival (unplanned heart failure hospitalization, left ventricular assist device [LVAD]/heart transplant, or death). Seventy-nine (9%) CS patients met the inclusion criteria (35% female, median age 57 years, mean LVEF 30.9%, median New York Heart Association class II [46%], mean number of GDMT agents 1.7, and mean KCMO score 31.8). Most (87%) were treated with immunosuppressive treatment. At follow-up (median 16 months), the mean number of GDMT agents increased to 2.2 (P=0.02), and the mean KCMO score to 70.1 (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisHeart Failure, SystolicCardiomyopathiesStroke VolumeHumansFemaleMaleMiddle AgedAgedImmunosuppressive AgentsAdultRetrospective StudiesVentricular Function, LeftTreatment OutcomeHeart TransplantationProgression-Free Survival

Stichwörter der Autor:innen

Cardiac sarcoidosisGuideline-directed medical therapyHeart failureImmunosuppression

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Mayo Clinic School of Graduate Medical Education.
  • Department of Cardiovascular Diseases, Mayo Clinic Rochester.
  • Mayo Clinic Alix School of Medicine.
  • Department of Diagnostic Radiology, Mayo Clinic Rochester.
  • Department of Cardiovascular Diseases, Mayo Clinic Florida.

Förderung

  • Center for Clinical and Translational Science

Zitieren

APA

Sykora, D., Bratcher, M., Churchill, R., Kim, B. M., Elwazir, M., Young, K., Ryan, S., Kolluri, N., Abou Ezzeddine, O., Bois, J., Giudicessi, J., Cooper, L., & Rosenbaum, A. (2024). Medical Therapy and Clinical Outcomes in Cardiac Sarcoidosis Patients With Systolic Heart Failure. Circulation Journal. https://doi.org/10.1253/circj.cj-24-0205

Vancouver

Sykora D, Bratcher M, Churchill R, Kim BM, Elwazir M, Young K, et al. Medical Therapy and Clinical Outcomes in Cardiac Sarcoidosis Patients With Systolic Heart Failure. Circulation Journal. 2024. doi:10.1253/circj.cj-24-0205

BibTeX
@article{Sykora2024,
  author = {Sykora, Daniel and Bratcher, Melanie and Churchill, Robert and Kim, B Michelle and Elwazir, Mohamed and Young, Kathleen and Ryan, Sami and Kolluri, Nikhil and Abou Ezzeddine, Omar and Bois, John and Giudicessi, John and Cooper, Leslie and Rosenbaum, Andrew},
  title = {Medical Therapy and Clinical Outcomes in Cardiac Sarcoidosis Patients With Systolic Heart Failure},
  journal = {Circulation Journal},
  year = {2024},
  doi = {10.1253/circj.cj-24-0205}
}
Kostenlos starten →